FGL2, a pivotal mediator of tumor–host immune-coagulation signaling, in malignancies, increasingly recognized as a key effector in cancer, driving progression via immune suppression and coagulation.

​​​

Our pioneering discovery that FGL2 gene silencing prevented tumor development in SCID mice, established FGL2 as a functionally significant mediator of oncogenesis.

 

In subsequent translational studies, we demonstrated markedly elevated FGL2 prothrombinase activity in peripheral blood of patients across multiple malignancies (Colon, Lung, Lymphoma, Prostate cancer and more), correlating with patients' subclinical disease state and independent of metabolic response - positioning FGL2 prothrombinase as a quantifiable biomarker directly reflective of active tumor biology, rather than treatment-related metabolic changes.

​

These findings provided the scientific basis for our proprietary functional assay: a non-invasive, real-time test measuring FGL2 prothrombinase activity with high sensitivity and analytical robustness, enabling frequent monitoring of disease progression in various malignancies, indipendent of treatment type, line & course.​

​​